

□ Other

Lab Formulary Intake Request

Complete this form to **request a new test, expand or limit indications for an existing test**, (i.e. appropriateness, utilization initiative or request an appropriateness of assessment of a test). The form must be completed and signed as outlined in the instructions below and contain all supporting documentation (as applicable).

The following must be submitted via email to Lab.Formulary@ahs.ca

☐ The completed and signed form ☐ All supporting documentation required Note - The preference is to have all fields in the form completed. However, the Lab Formulary Committee understands that depending on the development stage of a test/technology not all detailed information or only limited data is available; and that missing information will be generated in collaboration with the Lab Formulary Committee over time. If the request is of sufficient value to be considered for potential adoption to the formulary. **Requestor Information** Name **Position Program/Organization Phone** e-mail Requested Test Information (N/A if unknown) Name of test Test manufacturer Is test Health Canada approved? □ No ☐ Yes Reason for test request and appropriateness (attach relevant documentation to support request) Clinical question(s) addressed by the test (e.g. new standard of practice, cost savings, include relevant reference(s)) Target population □ Broadest Target Population ☐ Subpopulations (please specify) Purpose of test (check all that apply) ☐ Risk assessment □ Screening □ Diagnosis □ Surveillance ☐ Staging and prognosis ☐ Therapy selection □ Monitoring What is the impact on current practice (e.g., better outcomes, cost savings, quality) **Diagnostic Specimen** ☐ Blood ☐ Urine ☐ Tissue (specify Tissue type) ___ □ Other (specify) **Specimen Collection Process/Location** In-Hospital **Outside Hospital** ☐ Community collection location (specify) ☐ Under anesthetic ☐ Ward □ During surgery ☐ Biopsy ☐ Needle aspirate □ Endoscopy □ Doctor's office

21259(Rev2021-12) 1 of 3

☐ Home collection



Lab Formulary Intake Request

On a simon a sulla	sta al las contactos				
Specimen collect ☐ Nurse	ted by wnom □ Laboratory Staff	□ Physician	□ Patient		
Where is test pe	-	yo.o.a			
☐ Point of care s					
What technology is used for analysis					
☐ In situ hybridiz	ation	Chips and Mic	roarrays		
☐ Immuno-histo-chemistry		□ RNA □ miRNA			
☐ Immunoassays		□ cDNA	DNA		
		☐ SNPs	□ proteins		
☐ Mass spectron	ieti y	Whole Genom	e Sequencina		
□ Elisa		□ Platform? (specify)			
☐ Polymerase Chain Reaction (PCR)					
		Exome Seque	ncing Platform? (specify)		
Other (anacify)					
☐ Other (specify)					
	structure required				
• • • • • • • • • • • • • • • • • • • •	t. ☐ Point of Care	☐ Sequencers		zers	
☐ Couriers	☐ Other (specify)				
unknown Patienale for a constitution infractives					
Rationale for supporting infrastructure					
Dy whom one we	aulta analyssad				
By whom are res ☐ Informatician	Suits analyzed □ Pathologist/Clinica	I Doctoral Scient	ist □ Nurse □ Clinician		
☐ Patient (e.g., pre	•	□ Lab Staff	ist in winds in our line are		
□ Other (specify) _	3				
☐ Unknown					
Expected Busin					
☐ Point of Care	□ Dx service	□ Device/Kit	☐ Software/Algorithm		
Expected cost o	f Test		Expected/targeted Return on Inve	estment	
Is there anything else you would like to tell us about your technology?					

If Lab test is still under development complete the following page otherwise proceed to the authorization section on page 3

21259(Rev2021-12) 2 of 3



Lab Formulary Intake Request

Complete if Lab test is still under development					
	Complete if Lab test is still under development				
Stage of Development ☐ Discovery - research ongoing ☐ Proof of concept ☐ Pre-clinical validation in process ☐ Pre-clinical validation completed ☐ Clinical validation in progress ☐ Clinical validation completed					
Available data on ☐ Receiver Operating Characteristic Curve ☐ Sensitivity – positive and negative predictive values ☐ Specificity					
Expected regulatory pathway in each target market based on I					
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevice/ucm051530.htm)					
□ Classification of In Vitro Diagnostic Device (IVD) □ Medical Specialty □ Class (I / II / III) □ Premarket Notification (510k) to demonstrate that the device to be marketed is at least as safe and effective (i.e., substantially equivalent, to a legally marketed device that is not subject to PMA) □ Premarket Approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. □ Class I / II Exemption □ Humanitarian Device Exemption					
Stage of regulatory approval (if any) Stage	Expected time to regulatory approval				
State					
Date (dd-Mon-yyyy)					
	ered copyright/trademark)				
Date (dd-Mon-yyyy) Status and ownership of Intellectual Property □ Patent filing strategy □ Patents filed/priority date/ publication date □ Patents granted/priority date	ered copyright/trademark)				
Date (dd-Mon-yyyy) Status and ownership of Intellectual Property □ Patent filing strategy □ Patents filed/priority date/ publication date □ Patents granted/priority date □ Other intellectual property protection (e.g., proprietary database/register)					
Date (dd-Mon-yyyy) Status and ownership of Intellectual Property □ Patent filing strategy □ Patents filed/priority date/ publication date □ Patents granted/priority date □ Other intellectual property protection (e.g., proprietary database/registed) Declaration of Conflict of Interest	ulary Intake Request at this time.				
Date (dd-Mon-yyyy) Status and ownership of Intellectual Property □ Patent filing strategy □ Patents filed/priority date/ publication date □ Patents granted/priority date □ Other intellectual property protection (e.g., proprietary database/register) Declaration of Conflict of Interest □ I have no conflicts of interest to declare related to my Lab Formula I have interests to declare which may actually, potentially, or be	ulary Intake Request at this time. perceived to conflict with my Lab				

Authorization		
Signature	Date(dd-Mon-yyyy)	

21259(Rev2021-12) 3 of 3